FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1277-1278 March 25, 2004 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Milpied, N. PubMed Citation

The lymphomas are a heterogeneous group of cancers of the lymphoid system that are of increasing importance to the medical community. There has been a threefold increase in the incidence of these tumors for reasons that are incompletely understood, and the effect of therapy on the natural history of lymphomas has been dramatic. Without treatment, these disorders are almost invariably fatal — survival is measured in months to years, depending on the subtype. But most patients will benefit from irradiation, chemotherapy, biologic therapy, or combinations of these approaches, even if only transiently, and a proportion of them will be cured.

. . . [Full Text of this Article]

Source Information

From the Department of Medical Oncology, St. Bartholomew's Hospital, London.

Related Letters:

Intensive Therapy for Aggressive Lymphoma
Aguiar Bujanda D., Bohn Sarmiento U., Aguiar Morales J., Bolaños-Meade J., Herishanu Y., Zomas A., Skandalis A., Milpied N.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:98-100, Jul 1, 2004. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.